[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd-l1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd-l1":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,70,102,131,166,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100574058","68ga-nk224-pet-imaging-of-pd-l1-expression-in-cancers-100574058",false,"NCT06754345","68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);\n* (iii) patients who had scheduled 68Ga-NK224 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","90 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the evaluation of PD-L1 expression in primary and\u002For metastatic tumors, compared with histopathological results.",[25,26],"Tumor","PD-L1",[25,26,28,29],"PET\u002FCT","diagnosis","RECRUITING","2026-05-13",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":34},"2023-05-30",{"date":38,"type":21},"2026-11-30",{"name":40,"class":41},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100626950","pd-l1-targeting-peptide-probe-for-pet-imaging-of-solid-tumor-100626950","NCT07442292","PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor","Inclusion Criteria:\n\n1. Aged 18-75, male and female, with ECOG score of 0 or 1;\n2. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;\n3. underwent PD-L1 IHC examination before therapy;\n4. The expected survival was more than 26 weeks;\n5. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \\>= 4.0 x 10\\^9\u002FL or neutrophil \\>= 1.5 x 10\\^9\u002F:, PLT \\>= 100 x 10\\^9 \u002F L, Hb \\>= 90g \u002F L; Pt or APTT \\\u003C= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \\\u003C= 1.5 x ULT (upper limit of normal value), ALT \u002F AST \\\u003C= 2.5 upper limit of normal value or \\\u003C= 5 x ULT (subject with liver metastasis), ALP \\\u003C= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \\\u003C= 4.5 upper limit of normal value); BUN \\\u003C= 1.5 x ULT, SCR \\\u003C= 1.5 x ULT;\n6. According to RECIST1.1, there was at least one measurable target lesion;\n7. Understand and sign informed consent voluntarily with good compliance.\n\nExclusion Criteria:\n\n1. The function of liver and kidney was seriously abnormal;\n2. Preparation for pregnant, pregnant and lactating women;\n3. Inability to lie flat for half an hour;\n4. Suffering from claustrophobia or other mental disorders;\n5. Other researchers considered it unsuitable to participate in the trial.","75 Years",{"count":52,"type":21},40,"The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET\u002FCT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.",[55,56,57,58,26,59],"Lung Cancer (NSCLC)","Lung Cancer (SCLC)","Melanoma (Skin Cancer)","Melanoma Metastatic","PET \u002F CT","NOT_YET_RECRUITING","2026-03-03",{"date":63,"type":34},"2026-03-05",{"date":65,"type":21},"2026-02",{"date":67,"type":21},"2027-06",{"name":69,"class":41},"Peking University Cancer Hospital & Institute",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100616961","phase-1-ldrt-combined-with-pucotenlimab-and-standard-therapy-for-advanced-pancreatic-cancer-a-single-arm-study-100616961","NCT07312422","LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* ECOG score of 0 to 1;\n* Patients with histologically or cytologically confirmed pancreatic malignancy;\n* No prior treatment with PD-1 or PD-L1 inhibitors;\n* Presence of a radiotherapeutically eligible target lesion (excluding bone metastases);\n* Subjects voluntarily participate in the study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Previous history of radiotherapy;\n* Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.;\n* Active or clinically uncontrolled severe infections;\n* History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders;\n* Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures;\n* Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.",{"count":78,"type":21},10,"INTERVENTIONAL",[81,82],"PHASE1","PHASE2","To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.",[85,26,86,87,88],"Pancreatic Cancer","PD-1 Inhibitor","LDRT","Proterizumab",[90,91,87,92],"pancreatic cancer","PD-1 inhibitor","immunotherapy","2026-01-22",{"date":95,"type":34},"2026-01-26",{"date":97,"type":34},"2025-09-30",{"date":99,"type":21},"2026-10-30",{"name":101,"class":41},"Zhejiang Provincial People's Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":79,"phases":109,"briefSummary":111,"conditions":112,"keywords":119,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":42},"100593276","phase-4-efficacy-and-safety-of-iparomlimab-and-tuvonralimab-injection-in-combination-with-bevacizumab-after-progression-on-anti-pd-l1-therapy-in-advanced-melanoma-a-prospective-single-arm-exploratory-clinical-study-100593276","NCT07004335","Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria for enrollment:\n\n1. Age ≥18 years;\n2. Histologically-confirmed unresectable Stage III or IV melanoma, unsuitable for local therapy;\n3. Confirmed PD according to iRECIST within 12 weeks after receiving the last dose of anti-PD-(L)1 monotherapy or in combination with other treatments (including anti-CTLA-4) for at least two doses. (Up to 25% of participants may have received both anti-CTLA-4 and anti-PD-(L)1 treatment);\n4. Participants with BRAF\u002FCKIT\u002FNRAS gene mutations must have progressed after targeted therapy;\n5. Intolerant to chemotherapy or refused standard therapy;\n6. Toxicity from the most recent treatment recovered to grade 1 or below (except alopecia); if participants underwent major surgery or radiotherapy \\>30 Gy, they must have recovered from treatment-related toxicities\u002Fcomplications;\n7. Life expectancy of at least 3 months;\n8. Eastern Cooperative Oncology Group (ECOG) score: 0-1;\n9. At least one measurable lesion confirmed according to RECIST 1.1 criteria;\n10. Laboratory test results at screening must meet the following requirements:\n\n    a) Hematological tests must meet the following criteria (no blood\u002Fblood product transfusion, no correction with G-CSF or other hematopoietic stimulants within 14 days): i. Hemoglobin (Hb) ≥ 90 g\u002FL ii. Neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL iii. Platelet count (PLT) ≥ 100×10\\^9\u002FL b) Biochemical tests must meet the following criteria: i. Total bilirubin (TBIL) \\\u003C 1.5 × upper limit of normal (ULN) ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 ULN (\\\u003C5 ULN for participants with liver metastasis) iii. Serum creatinine (Cr) ≤ 1.5 ULN or endogenous creatinine clearance rate \\> 50ml\u002Fmin (Cockcroft-Gault formula) iv. Urine routine test results show urine protein (UPRO) \\\u003C 2+ or 24-hour urine protein quantification \\\u003C1g;\n11. Women of childbearing potential must have taken reliable contraceptive measures, had a negative pregnancy test (serum or urine) within 7 days before enrollment, and agree to use appropriate contraception during the trial and for 6 months after the last administration of the investigational drug. Nursing mothers should discontinue breastfeeding during the whole trial period and for 6 months after the last administration of the investigational drug to avoid the drug affecting the infant through milk. For men, they must agree to use appropriate contraception during the trial and for 120 days after the last administration of the investigational drug or have undergone surgical sterilization;\n12. Provide written informed consent, and are expected to have good compliance with the study protocol.\n\nExclusion Criteria:\n\nParticipants meeting any of the following will be excluded:\n\n1. Any active autoimmune disease or a history of autoimmune disease requiring treatment (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, hepatitis, pituitary炎, vasculitis, nephritis, hyperthyroidism; participants with vitiligo; childhood asthma that has completely resolved without any intervention in adulthood can be included; participants with asthma requiring bronchodilators for medical intervention cannot be included);\n2. Received more than 10 mg of prednisolone or other immunosuppressive therapy within seven days prior to study treatment;\n3. Severe allergic reaction to other monoclonal antibodies;\n4. Uncontrolled cardiac clinical symptoms or disease, such as: heart failure of NYHA class 2 or above; unstable angina; myocardial infarction within the past year; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; QTc \\>450 ms (males); QTc \\>470 ms (females);\n5. Underwent any major surgery requiring general anesthesia within 28 days prior to the first dose;\n6. Active infection, unexplained fever ≥38.5°C within seven days prior to medication, or baseline white blood cell count \\>15×10⁹\u002FL; or suppurative and chronic infections, non-healing wounds;\n7. With bone metastasis who received palliative radiotherapy to \\>5% of the bone marrow area within four weeks prior to study entry;\n8. Known allergy to recombinant humanized anti-PD-(L)1 monoclonal antibody drugs, recombinant humanized anti-CTLA-4 monoclonal antibody, and\u002For their components;\n9. Concurrent other malignancies;\n10. Concurrent participation in other interventional clinical trials;\n11. HIV positive; HCV positive; HBsAg or HBcAb positive with detectable HBV DNA copies (quantitative detection limit of 500 IU\u002Fml);\n12. Received live vaccine vaccination within four weeks prior to treatment initiation;\n13. Ocular melanoma;\n14. With active brain metastasis (previously untreated asymptomatic brain metastasis patients with ≤3 brain lesions and longest diameter \\\u003C1 cm can be included. Previously treated brain metastasis patients who are clinically stable with no new or enlarged brain metastasis and have not used steroids for ≥14 days prior to study intervention can be included); other severe, acute, or chronic medical or mental disorders or laboratory abnormalities that may increase the risk associated with study participation or may interfere with the interpretation of study results, as judged by the investigator.",{"count":52,"type":21},[110],"PHASE4","Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer. However, the efficacy and safety of this regimen in melanoma patients with acquired resistance to immunotherapy remain unexplored and require further validation.\n\nThis study aims to evaluate the efficacy and safety of the Iparomlimab, Tuvonralimab, and Bevacizumab combination in patients with immune-resistant melanoma. Furthermore, it will analyze and compare treatment responses among different melanoma subtypes to identify optimal treatment strategies for clinical practice.",[113,114,115,116,117,118],"PD-(L)1","CTLA-4","Advanced Melanoma","Iparomlimab","Tuvonralimab","Bevacizumab",[120,121],"Immunotherapy","Immune Checkpoint Inhibitors","2025-05-27",{"date":124,"type":34},"2025-06-04",{"date":126,"type":21},"2025-07-01",{"date":128,"type":21},"2029-01-31",{"name":130,"class":41},"Hebei Medical University Fourth Hospital",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":165},"100564959","a-prospective-real-world-evidence-study-prowes-for-concordance-rate-of-blood-based-3d-genome-conformation-mapping-episwitch-cirt-to-identify-likelihood-of-response-and-actual-response-rates-to-pd-l-1-checkpoint-inhibitors-across-multiple-oncological-indications-100564959","NCT06635954","A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.","PROWES","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Stage III or IV cancer\n3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.\n4. ECOG performance status ≤ 2\n5. Clinically eligible for ICI therapy\n6. Able to read, understand and provide written informed consent.\n7. Willing and able to comply with the study requirements\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. History of bone marrow or organ transplant\n3. Contra indication for receiving Immune Check Point inhibitor.",{"count":139,"type":21},2000,"The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.",[142,120,143,26,144],"Cancer","PD-1","Immune Checkpoint Therapy",[92,146,147,148,149,150,151,152,153,154,143,26],"immune checkpoint inhibitor","ICI therapy","ICI","Immune Checkpoint Inhibitor therapy","Episwitch","Episwitch CiRT","Immune Related Adverse Event","IRAE","cancer","2025-03-12",{"date":157,"type":34},"2025-03-17",{"date":159,"type":34},"2024-05-14",{"date":161,"type":21},"2027-05-14",{"name":163,"class":164},"Oxford Biodynamics Inc.","INDUSTRY",3,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":173,"targetDuration":4,"studyType":79,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100569842","phase-2-neoadjuvant-therapy-of-targeted-immunotherapy-combined-with-chemotherapy-for-locally-advanced-hnscc-100569842","NCT06699498","Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC","Phase II Clinical Study of Neoadjuvant Therapy With Benmelstobart Combined With Anlotinib and Chemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Age 18-75 years old;\n* ECOG PS score of 0-1;\n* Pathologically confirmed, untreated patients with head and neck squamous cell carcinoma, classified as stage III, IVa according to AJCC (8th edition), including hypopharyngeal cancer, laryngeal cancer, and oral cancer;\n* Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the trial drug, or have undergone sterilization. For male participants, they must agree to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the trial drug, or have undergone surgical sterilization;\n* Signed the informed consent form with their own consent and have good compliance.\n\nExclusion Criteria:\n\n* Received previous PD-1\u002FPD-L1\u002FCTLA-4 antibody therapy;\n* Tumor invasion of major blood vessels;\n* Patients requiring systemic use of glucocorticoids (\\>10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days before administration or during treatment. Inhaled or local use of steroids and adrenal corticosteroids at doses \\>10mg\u002Fday prednisone equivalent are allowed in the absence of active autoimmune diseases. Adrenal corticosteroid replacement therapy not exceeding 10mg\u002Fday prednisone equivalent is also allowed;\n* Presence of any history of active immune or autoimmune diseases, or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* Active or uncontrolled severe infection (≥NCI CTCAE v5.0 Grade 2 infection) within 4 weeks before enrollment;\n* Abnormal coagulation function (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or APTT \\> 1.5 ULN), tendency to bleed, or receiving thrombolytic or anticoagulant therapy; Note: Small doses of heparin (adult daily dose of 6,000-12,000 U) or small doses of aspirin (daily dose ≤ 100 mg) for preventive purposes are allowed provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\n* Patients with imaging showing tumor invasion of vital perivascular tissue or whose tumor is likely to invade vital blood vessels during subsequent study and cause fatal bleeding as judged by the investigator;\n* Patients with any signs or history of bleeding diathesis, regardless of severity;\n* patients with any bleeding or hemorrhage event ≥ CTCAE Grade 2 within 4 weeks before enrollment, presence of unhealed wounds, ulcers, or fractures;\n\nAbnormalities in major organ functions:\n\n* Abnormal blood routine examination (received blood transfusion or blood products, or used G-CSF and other hematopoietic growth factors for correction within 14 days):\n\n  1. Hemoglobin (HB) \\\u003C 90g\u002FL;\n  2. Absolute neutrophil count (ANC) \\\u003C 1.5 × 109\u002FL;\n  3. Platelets (PLT) \\\u003C 100 × 109\u002FL;\n\n     * Abnormal biochemical examination:\n\n  \u003C!-- -->\n\n  1. Total bilirubin (TBIL) \\> 1.5 \\* upper limit of normal (ULN);\n  2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2.5 × ULN;\n  3. Serum creatinine (Cr) \\> 1.5 × ULN or creatinine clearance rate (CCr) \\\u003C 60ml\u002Fmin; ③ Abnormal Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) \\\u003C normal lower limit (60%);\n\n     * Abnormal thyroid function: TSH \\> upper limit of normal (ULN) with abnormal T3 and T4 levels;\n\n       * Renal insufficiency: Urine routine test indicating urine protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0g;\n       * Grade I or higher myocardial ischemia or myocardial infarction, arrhythmia (including QTc ≥ 480ms), and ≥ Grade 2 congestive heart failure (New York Heart Association (NYHA) classification) within 6 months before enrollment;\n       * Diagnosed with other malignancies within 3 years before enrollment;\n       * Patients with any severe and\u002For uncontrolled diseases, including:\n\n  \u003C!-- -->\n\n  1. Patients with uncontrolled blood pressure (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); Grade I or higher myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 430ms), and Grade I cardiac insufficiency (NYHA classification);\n  2. Active or uncontrolled severe infections;\n  3. Diseases such as cirrhosis, decompensated liver disease, active hepatitis HBV or HCV;\n  4. Poorly controlled diabetes (fasting blood glucose (FBG) \\> 10mmol\u002FL);\n  5. Urine routine test indicating urine protein ≥ 2+, and confirmed 24-hour urine protein \\> 1.0g;\n\n     \\- Presence of long-term unhealed wounds or fractures;\n\n     \\- Pulmonary hemorrhage graded \\> 1 by NCI CTC AE V4.0 within 4 weeks before enrollment; hemorrhage in other locations graded \\> 2 by NCI CTC AE V4.0 within 4 weeks before enrollment; patients with a tendency to bleed (such as active peptic ulcer) or receiving thrombolytic or anticoagulant therapy such as warfarin, heparin, or similar drugs;\n\n     \\- History of gastrointestinal perforation and\u002For fistula within 6 months before selected treatment; or history of arterial\u002Fvenous thrombotic events such as cerebrovascular accidents (including transient ischemic attacks), deep venous thrombosis, and pulmonary embolism;\n\n     \\- Imaging showing tumor invasion of vital blood vessels or patients whose tumor is likely to invade vital blood vessels and cause fatal bleeding during subsequent study as judged by the investigator;\n\n     \\- Clinically significant ascites, including any ascites detectable by physical examination, ascites that has been treated or still requires treatment, and patients with only a small amount of ascites shown by imaging but asymptomatic are eligible;\n\n     \\- Uncontrolled metabolic disorders or other non-malignant tumor organ or systemic diseases or secondary reactions to cancer that can lead to high medical risks and\u002For uncertainty in survival evaluation;\n\n     \\- Participated in other anti-cancer drug clinical trials within 4 weeks before enrollment;\n     * Patients with a history of psychotropic drug abuse who cannot quit or have mental disorders;\n     * Any accompanying diseases or other conditions that the investigator judges as seriously endangering the safety of the patient, potentially confusing the study results, or affecting the patient's completion of this study.",{"count":174,"type":21},45,[82],"Exploring the safety and effectiveness of neoadjuvant therapy using benmelstobart combined with anlotinib and chemotherapy for locally advanced squamous cell carcinoma of the head and neck patients.",[178,179,26,180],"Head and Neck Squamous Cell Carcinoma","Neoadjuvant Therapy","Anlotinib","2024-11-19",{"date":183,"type":34},"2024-11-21",{"date":185,"type":21},"2024-12-03",{"date":187,"type":21},"2027-12-01",{"name":189,"class":41},"The First Affiliated Hospital with Nanjing Medical University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":79,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100469819","phase-2-envafolimab-plus-chemoradiotherapy-for-locally-advanced-npc-a-prospective-single-armed-phase-ii-trial-100469819","NCT05397769","Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.","Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.","Inclusion Criteria:\n\n* ECOG 0-1\n* histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx\n* stage III-IVa （AJCC\u002FUICC 8th ）, untreated NPC patients\n* NE≥ 1.5×10E9\u002FL, HGB ≥ 100g\u002FL and PLT ≥100×10E9\u002FL\n* ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN\n* creatinine\\\u003C1.5×ULN\n\nExclusion Criteria:\n\n* recurrent or metastatic NPC patients\n* histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx\n* already received radiation or chemotherapy\n* pregnant or lactating women, or women of childbearing age without birth control\n* HIV (+)\n* had other cancers before\n* used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before\n* complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose\n* with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)\n* use of massive dose of glucocorticoids within 4 weeks before enrollment\n* laboratory test values do not meet relevant standards within 7 days before enrollment\n* significantly lower functions of heart, liver, lung, kidney and bone marrow\n* serious or uncontrolled medical diseases or infections\n* participating other clinical trial in the same time\n* HBsAg (+) and HBV DNA \\>1×10E3 copiers \u002FmL\n* HCV (+) unless HCV RNA PCR(-)\n* with any other treatment contraindications","65 Years",{"count":199,"type":21},36,[82],"Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy\u002F30-33f, 5d\u002Fw,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.",[203,204,205,26],"Locally Advanced Nasopharyngeal Carcinoma","Envafolimab","Induction Chemotherapy","2022-08-09",{"date":208,"type":34},"2022-08-10",{"date":210,"type":34},"2022-06-08",{"date":212,"type":21},"2026-12-31",{"name":214,"class":41},"Sun Yat-sen University"]